When administering clinical trial drugs to patients with house dust mite allergic rhinitis, safety/tolerance is comparatively evaluated as the primary outcome, and symptom improvement and immune activity of the disease are comparatively evaluated as secondary outcome.
Age range
19 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Vital signs
Timeframe: 1 day before dosing, Post-study visit(within 15 days after clinical completion)
Health examination
Timeframe: 1 day before dosing, Post-study visit(within 15 days after clinical completion)
laboratory test
Timeframe: 1 day before dosing, Post-study visit(within 15 days after clinical completion)
laboratory test
Timeframe: 1 day before dosing, Post-study visit(within 15 days after clinical completion)
laboratory test
Timeframe: 1 day before dosing, Post-study visit(within 15 days after clinical completion)
Electrocardiography
Timeframe: 1 day before dosing, Post-study visit(within 15 days after clinical completion)
Local Adverse Event
Timeframe: 1 day before dosing, Post-study visit(within 15 days after clinical completion)
systemic adverse event
Timeframe: 1 day before dosing, Post-study visit(within 15 days after clinical completion)